<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823225</url>
  </required_header>
  <id_info>
    <org_study_id>MC-UK.3/AVK</org_study_id>
    <secondary_id>EudraCT number 2007-005916-15</secondary_id>
    <nct_id>NCT00823225</nct_id>
  </id_info>
  <brief_title>Urokinase Therapy in Patients With Diabetic Foot Syndrome</brief_title>
  <official_title>Low Dose Urokinase Therapy in Patients With Diabetic Foot Syndrome and Critical Limb Ischemia Versus Conventional Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>medac GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the additional therapy with low dose
      urokinase is more effective than only a conventional standard therapy concerning
      ulcer-healing, rate of major amputation and survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with diabetic foot ulceration and critical limb ischemia have a high risk of major
      amputation, especially if limbs can not be revascularized. Urokinase is effective in critical
      limb ischemia by lowering fibrinogen and might improve outcomes. The effect and safety of
      urokinase treatment was investigated in a phase II clinical trial. Based on the results this
      trial was planned to investigate the effect and safety of an additional therapy with
      urokinase versus a single conventional therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment of study patients
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major amputation free survival</measure>
    <time_frame>Within twelve months after randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total survival, major amputation rate, rate of complete ulcer healing, rate of adverse events</measure>
    <time_frame>Within twelve month after randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Diabetic Foot</condition>
  <condition>Arterial Occlusive Disease</condition>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>A: Standard therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Urokinase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard therapy</intervention_name>
    <description>wound debridement, moist wound dressing</description>
    <arm_group_label>A: Standard therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urokinase</intervention_name>
    <description>Daily infusion up to 21 applications, dose dependent on fibrinogen level:
&gt; 2,5g/l 1 000 000 IU, &lt; 2,5g/l 500 000 IU</description>
    <arm_group_label>B: Urokinase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic patients with angiopathic or angioneuropathic diabetic foot syndrome and
             criticial limb ischemia

          -  No surgical or interventional treatment option

          -  No healing tendency of ulcerations despite of antibiosis and wound debridement after
             two-week treatment

          -  Fibrinogen &gt; 4.0 g/l

          -  No previous major amputation

        Exclusion Criteria:

          -  Prior treatment of the current ulceration with urokinase

          -  Need for dialysis and/or creatinine-clearance &lt; 20ml/min

          -  INR &gt; 1,5 at screening

          -  Any kind of cerebral event within 3 months prior inclusion

          -  Proliferative retinopathy

          -  Uncontrolled hypertension

          -  Hemorraghic diathesis

          -  Gastrointestinal bleeding

          -  Pregnancy

          -  No compliance and/or participation in another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Schellong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Dresden-Friedrichstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Franziskus Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund Nord GmbH</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Neustadt</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weißeritztal-Kliniken GmbH</name>
      <address>
        <city>Freital</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Karlsbad Langensteinbach</name>
      <address>
        <city>Karlsbad</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2015</last_update_posted>
  <responsible_party>
    <name_title>Prof.Dr.med. S. Schellong</name_title>
    <organization>Städtisches Krankenhaus Dresden-Friedrichstadt, Friedrichstr. 41, 01067 Dresden, Germany</organization>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>urokinase</keyword>
  <keyword>ulcer healing</keyword>
  <keyword>major amputation</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

